Standout Papers

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema 2016 2026 2019 2022 671
  1. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema (2016)
    John A. Wells, Adam R. Glassman et al. Ophthalmology

Immediate Impact

1 from Science/Nature 58 standout
Sub-graph 1 of 22

Citing Papers

Age-Related Macular Degeneration
2024 Standout
Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
2024 Standout
2 intermediate papers

Works of G. Robert Hampton being referenced

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
2016 Standout

Author Peers

Author Last Decade Papers Cites
G. Robert Hampton 843 679 9 94 14 911
Benjamin Nicholson 823 448 25 135 16 942
Jonathan Dowler 752 463 4 124 27 820
Raymond Wong 755 567 14 96 25 925
Elie Motulsky 868 717 2 79 30 962
Christoph Ehlken 898 680 5 193 34 1.1k
Srilaxmi Bearelly 962 657 3 299 37 1.1k
Justin L. Gottlieb 939 574 15 102 26 1.1k
M.F. White 744 440 9 163 23 844
Matthew T. Witmer 492 305 24 104 26 856
G. Atma Vemulakonda 902 636 5 73 18 1.0k

All Works

Loading papers...

Rankless by CCL
2026